{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T23:29:06Z","timestamp":1786318146397,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100008383","name":"Stichting ParkinsonFonds","doi-asserted-by":"publisher","award":["NL1903"],"award-info":[{"award-number":["NL1903"]}],"id":[{"id":"10.13039\/501100008383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-026-01376-x","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:34:11Z","timestamp":1779230051000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of faecal microbiota transplantation in Parkinson\u2019s disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Vlada O.","family":"Chernova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita WY","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuyue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Corcione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Benech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joffrey","family":"van Prehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed J.","family":"Kuijper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Fiorella","family":"Contarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"1376_CR1","unstructured":"World Health Organization. Parkinson Disease Geneva: [Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/parkinson-disease (World Health Organization, 2023)."},{"key":"1376_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/mds.27556","volume":"34","author":"DP Breen","year":"2019","unstructured":"Breen, D. P., Halliday, G. M. & Lang, A. E. Gut-brain axis and the spread of alpha-synuclein pathology: Vagal highway or dead end? Mov. Disord. 34, 307\u2013316 (2019).","journal-title":"Mov. Disord."},{"key":"1376_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/1877718X241305711","volume":"15","author":"M Spott","year":"2025","unstructured":"Spott, M. et al. Addressing the need for standardization of symptomatic medication documentation in Parkinson\u2019s disease clinical research: a call to action. J. Parkinsons Dis. 15, 227\u2013235 (2025).","journal-title":"J. Parkinsons Dis."},{"key":"1376_CR4","unstructured":"George DeMaagd A. P. Parkinson\u2019s disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. Pharm. Ther. 40, 504 (2015)."},{"key":"1376_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40035-023-00392-8","volume":"12","author":"X Zhang","year":"2023","unstructured":"Zhang, X., Tang, B. & Guo, J. Parkinson\u2019s disease and gut microbiota: from clinical to mechanistic and therapeutic studies. Transl. Neurodegener. 12, 59 (2023).","journal-title":"Transl. Neurodegener."},{"key":"1376_CR6","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.1007\/s12035-024-04584-9","volume":"62","author":"Z Ran","year":"2025","unstructured":"Ran, Z. et al. Parkinson\u2019s disease and the microbiota-gut-brain axis: metabolites, mechanisms, and innovative therapeutic strategies targeting the gut microbiota. Mol. Neurobiol. 62, 5273\u20135296 (2025).","journal-title":"Mol. Neurobiol."},{"key":"1376_CR7","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/07853890.2021.1890330","volume":"53","author":"E Menozzi","year":"2021","unstructured":"Menozzi, E., Macnaughtan, J. & Schapira, A. H. V. The gut-brain axis and Parkinson disease: clinical and pathogenetic relevance. Ann. Med 53, 611\u2013625 (2021).","journal-title":"Ann. Med"},{"key":"1376_CR8","first-page":"S21","volume":"10","author":"MF Contarino","year":"2023","unstructured":"Contarino, M. F., van Hilten, J. J. & Kuijper, E. J. Targeting the gut-brain axis with fecal microbiota transplantation: considerations on a potential novel treatment for Parkinson\u2019s disease. Mov. Disord. Clin. Pr. 10, S21\u2013S25 (2023).","journal-title":"Mov. Disord. Clin. Pr."},{"key":"1376_CR9","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","volume":"103","author":"S Kim","year":"2019","unstructured":"Kim, S. et al. Transneuronal propagation of pathologic alpha-synuclein from the gut to the brain models Parkinson\u2019s disease. Neuron 103, 627\u201341 e7 (2019).","journal-title":"Neuron"},{"key":"1376_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70003","volume":"30","author":"H Yang","year":"2024","unstructured":"Yang, H. et al. Fecal microbiota from patients with Parkinson\u2019s disease intensifies inflammation and neurodegeneration in A53T mice. CNS Neurosci. Ther. 30, e70003 (2024).","journal-title":"CNS Neurosci. Ther."},{"key":"1376_CR11","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","volume":"167","author":"TR Sampson","year":"2016","unstructured":"Sampson, T. R. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson\u2019s disease. Cell 167, 1469\u201380 e12 (2016).","journal-title":"Cell"},{"key":"1376_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2454937","volume":"17","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson\u2019s disease. Gut Microbes 17, 2454937 (2025).","journal-title":"Gut Microbes"},{"key":"1376_CR13","doi-asserted-by":"crossref","unstructured":"Maini Rekdal V., Bess E. N., Bisanz J. E., Turnbaugh P. J. & Balskus E. P. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science 364, eaau6323 (2019).","DOI":"10.1126\/science.aau6323"},{"key":"1376_CR14","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","volume":"27","author":"J van Prehn","year":"2021","unstructured":"van Prehn, J. et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin. Microbiol. Infect. 27, S1\u2013S21 (2021).","journal-title":"Clin. Microbiol. Infect."},{"key":"1376_CR15","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","volume":"73","author":"S Johnson","year":"2021","unstructured":"Johnson, S. et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of clostridioides difficile infection in adults. Clin. Infect. Dis. 73, e1029\u2013e1044 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"1376_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fcimb.2020.00098","volume":"10","author":"KEW Vendrik","year":"2020","unstructured":"Vendrik, K. E. W. et al. Fecal microbiota transplantation in neurological disorders. Front. Cell Infect. Microbiol. 10, 98 (2020).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"1376_CR17","doi-asserted-by":"publisher","first-page":"e16163","DOI":"10.1097\/MD.0000000000016163","volume":"98","author":"H Huang","year":"2019","unstructured":"Huang, H. et al. Fecal microbiota transplantation to treat Parkinson\u2019s disease with constipation: a case report. Medicine 98, e16163 (2019).","journal-title":"Medicine"},{"key":"1376_CR18","doi-asserted-by":"crossref","unstructured":"Scheperjans F., et al. Fecal microbiota transplantation for treatment of Parkinson disease. JAMA Neurol. 81, 925\u2013938 (2024).","DOI":"10.1001\/jamaneurol.2024.2305"},{"key":"1376_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102563","volume":"71","author":"A Bruggeman","year":"2024","unstructured":"Bruggeman, A. et al. Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson\u2019s disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial. EClinicalMedicine 71, 102563 (2024).","journal-title":"EClinicalMedicine"},{"key":"1376_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2284247","volume":"15","author":"Y Cheng","year":"2023","unstructured":"Cheng, Y. et al. Efficacy of fecal microbiota transplantation in patients with Parkinson\u2019s disease: clinical trial results from a randomized, placebo-controlled design. Gut Microbes 15, 2284247 (2023).","journal-title":"Gut Microbes"},{"key":"1376_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1104759","volume":"14","author":"HL DuPont","year":"2023","unstructured":"DuPont, H. L. et al. Fecal microbiota transplantation in Parkinson\u2019s disease-a randomized repeat-dose, placebo-controlled clinical pilot study. Front. Neurol. 14, 1104759 (2023).","journal-title":"Front. Neurol."},{"key":"1376_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2025.106086","volume":"130","author":"J Wang","year":"2025","unstructured":"Wang, J. et al. Colonoscopic fecal microbiota transplantation for mild-to-moderate Parkinson\u2019s disease: a randomized controlled trial. Brain Behav. Immun. 130, 106086 (2025).","journal-title":"Brain Behav. Immun."},{"key":"1376_CR23","unstructured":"Group OLoEW. The Oxford 2011 Levels of Evidence (University of Oxford, 2011)."},{"key":"1376_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12934-021-01589-0","volume":"20","author":"XY Kuai","year":"2021","unstructured":"Kuai, X. Y. et al. Evaluation of fecal microbiota transplantation in Parkinson\u2019s disease patients with constipation. Micro. Cell Fact. 20, 98 (2021).","journal-title":"Micro. Cell Fact."},{"key":"1376_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106791","volume":"207","author":"A Segal","year":"2021","unstructured":"Segal, A., Zlotnik, Y., Moyal-Atias, K., Abuhasira, R. & Ifergane, G. Fecal microbiota transplant as a potential treatment for Parkinson\u2019s disease - a case series. Clin. Neurol. Neurosurg. 207, 106791 (2021).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"1376_CR26","doi-asserted-by":"publisher","first-page":"e22035","DOI":"10.1097\/MD.0000000000022035","volume":"99","author":"LJ Xue","year":"2020","unstructured":"Xue, L. J. et al. Fecal microbiota transplantation therapy for Parkinson\u2019s disease: A preliminary study. Medicine 99, e22035 (2020).","journal-title":"Medicine"},{"key":"1376_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105410","volume":"111","author":"VO Chernova","year":"2023","unstructured":"Chernova, V. O. et al. Fecal microbiota transplantation for Parkinson\u2019s disease using levodopa - carbidopa intestinal gel percutaneous endoscopic gastro-jejeunal tube. Parkinsonism Relat. Disord. 111, 105410 (2023).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1376_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41531-025-01061-5","volume":"11","author":"M De Sciscio","year":"2025","unstructured":"De Sciscio, M. et al. Faecal microbiota transplant in Parkinson\u2019s disease: pilot study to establish safety & tolerability. npj Parkinsons Dis. 11, 203 (2025).","journal-title":"npj Parkinsons Dis."},{"key":"1376_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00612-y","volume":"7","author":"X Ge","year":"2017","unstructured":"Ge, X. et al. Potential role of fecal microbiota from patients with slow transit constipation in the regulation of gastrointestinal motility. Sci. Rep. 7, 441 (2017).","journal-title":"Sci. Rep."},{"key":"1376_CR30","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cell.2015.02.047","volume":"161","author":"JM Yano","year":"2015","unstructured":"Yano, J. M. et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 161, 264\u2013276 (2015).","journal-title":"Cell"},{"key":"1376_CR31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/gutjnl-2022-328166","volume":"72","author":"N Prochazkova","year":"2023","unstructured":"Prochazkova, N. et al. Advancing human gut microbiota research by considering gut transit time. Gut 72, 180\u2013191 (2023).","journal-title":"Gut"},{"key":"1376_CR32","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3233\/JPD-212610","volume":"12","author":"S Polgar","year":"2022","unstructured":"Polgar, S. et al. The placebo response in double-blind randomised trials evaluating regenerative therapies for Parkinson\u2019s disease: a systematic review and meta-analysis. J. Parkinsons Dis. 12, 759\u2013771 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"1376_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41531-021-00156-z","volume":"7","author":"S Romano","year":"2021","unstructured":"Romano, S. et al. Meta-analysis of the Parkinson\u2019s disease gut microbiome suggests alterations linked to intestinal inflammation. npj Parkinsons Dis. 7, 27 (2021).","journal-title":"npj Parkinsons Dis."},{"key":"1376_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577126","volume":"339","author":"Z Shi","year":"2020","unstructured":"Shi, Z. et al. Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study. J. Neuroimmunol. 339, 577126 (2020).","journal-title":"J. Neuroimmunol."},{"key":"1376_CR35","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/ismej.2016.176","volume":"11","author":"M Lopez-Siles","year":"2017","unstructured":"Lopez-Siles, M., Duncan, S. H., Garcia-Gil, L. J. & Martinez-Medina, M. Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics. ISME J. 11, 841\u2013852 (2017).","journal-title":"ISME J."},{"key":"1376_CR36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41531-025-00894-4","volume":"11","author":"ME Krueger","year":"2025","unstructured":"Krueger, M. E. et al. Comparative analysis of Parkinson\u2019s and inflammatory bowel disease gut microbiomes reveals shared butyrate-producing bacteria depletion. npj Parkinsons Dis. 11, 50 (2025).","journal-title":"npj Parkinsons Dis."},{"key":"1376_CR37","doi-asserted-by":"crossref","unstructured":"Velma T. E. et al. Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson\u2019s disease. Mol. Neurodegener. 16, 6 (2021).","DOI":"10.1186\/s13024-021-00427-6"},{"key":"1376_CR38","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/s41591-022-01964-3","volume":"28","author":"G Ianiro","year":"2022","unstructured":"Ianiro, G. et al. Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases. Nat. Med. 28, 1913\u20131923 (2022).","journal-title":"Nat. Med."},{"key":"1376_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.pep.2013.10.018","volume":"94","author":"K Zhang","year":"2014","unstructured":"Zhang, K. & Ni, Y. Tyrosine decarboxylase from Lactobacillus brevis: soluble expression and characterization. Protein Expr. Purif. 94, 33\u201339 (2014).","journal-title":"Protein Expr. Purif."},{"key":"1376_CR40","unstructured":"VH Innovation. Covidence Systematic Review Software (VH Innovation, 2025)."},{"key":"1376_CR41","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251314820","volume":"18","author":"N Ragard","year":"2025","unstructured":"Ragard, N. et al. Validation methods for encapsulated faecal microbiota transplantation: a scoping review. Ther. Adv. Gastroenterol. 18, 17562848251314820 (2025).","journal-title":"Ther. Adv. Gastroenterol."},{"key":"1376_CR42","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ebiom.2019.02.023","volume":"41","author":"LE Papanicolas","year":"2019","unstructured":"Papanicolas, L. E. et al. Bacterial viability in faecal transplants: Which bacteria survive? EBioMedicine 41, 509\u2013516 (2019).","journal-title":"EBioMedicine"},{"key":"1376_CR43","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1136\/gutjnl-2025-335077","volume":"74","author":"S Kamath","year":"2025","unstructured":"Kamath, S. et al. Translational strategies for oral delivery of faecal microbiota transplantation. Gut 74, 2096\u20132117 (2025).","journal-title":"Gut"},{"key":"1376_CR44","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.chom.2023.03.020","volume":"31","author":"S Porcari","year":"2023","unstructured":"Porcari, S. et al. Key determinants of success in fecal microbiota transplantation: From microbiome to clinic. Cell Host Microbe 31, 712\u2013733 (2023).","journal-title":"Cell Host Microbe"},{"key":"1376_CR45","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1016\/j.cell.2025.05.014","volume":"188","author":"O DeLeon","year":"2025","unstructured":"DeLeon, O. et al. Microbiome mismatches from microbiota transplants lead to persistent off-target metabolic and immunomodulatory effects. Cell 188, 3927\u201341 e13 (2025).","journal-title":"Cell"},{"key":"1376_CR46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1556\/AMicr.56.2009.1.8","volume":"56","author":"M Thakur","year":"2009","unstructured":"Thakur, M. & Azmi, W. Biotransformation of L-tyrosine to tyramine by the growing cells of Lactococcus lactis. Acta Microbiol. Immunol. Hung. 56, 101\u2013114 (2009).","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"1376_CR47","doi-asserted-by":"crossref","unstructured":"Yadegar A., et al. Fecal microbiota transplantation: current challenges and future landscapes. Clin. Microbiol. Rev. 37, e00060-22 (2024).","DOI":"10.1128\/cmr.00060-22"},{"key":"1376_CR48","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1093\/ecco-jcc\/jjae043","volume":"18","author":"E van Lingen","year":"2024","unstructured":"van Lingen, E. et al. Faecal microbiota transplantation engraftment after budesonide or placebo in patients with active ulcerative colitis using pre-selected donors: a randomized pilot study. J. Crohns Colitis 18, 1381\u20131393 (2024).","journal-title":"J. Crohns Colitis"},{"key":"1376_CR49","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/ecco-jcc\/jjv203","volume":"10","author":"S Vermeire","year":"2016","unstructured":"Vermeire, S. et al. Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J. Crohns Colitis 10, 387\u2013394 (2016).","journal-title":"J. Crohns Colitis"},{"key":"1376_CR50","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/apt.14387","volume":"47","author":"P Kump","year":"2018","unstructured":"Kump, P. et al. The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment Pharm. Ther. 47, 67\u201377 (2018).","journal-title":"Aliment Pharm. Ther."},{"key":"1376_CR51","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).","journal-title":"BMJ"},{"key":"1376_CR52","unstructured":"Cochrane Collaboration. Cochrane Central Register of Controlled Trials (CENTRAL). Available from: https:\/\/www.cochranelibrary.com\/central\/about-central (John Wiley & Sons)."},{"key":"1376_CR53","unstructured":"U.S. National Library of Medicine. ClinicalTrials.gov Bethesda (MD)no date. Available from: https:\/\/clinicaltrials.gov\/."},{"key":"1376_CR54","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.parkreldis.2015.10.006","volume":"21","author":"K Horvath","year":"2015","unstructured":"Horvath, K. et al. Minimal clinically important difference on the motor examination part of MDS-UPDRS. Parkinsonism Relat. Disord. 21, 1421\u20131426 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1376_CR55","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mds.26960","volume":"32","author":"K Horvath","year":"2017","unstructured":"Horvath, K. et al. Minimal clinically important differences for the experiences of daily living parts of Movement Disorder Society-sponsored Unified Parkinson\u2019s disease rating scale. Mov. Disord. 32, 789\u2013793 (2017).","journal-title":"Mov. Disord."},{"key":"1376_CR56","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.parkreldis.2018.08.018","volume":"58","author":"A Makkos","year":"2019","unstructured":"Makkos, A., Kovacs, M., Pinter, D., Janszky, J. & Kovacs, N. Minimal clinically important difference for the historic parts of the Unified Dyskinesia Rating Scale. Parkinsonism Relat. Disord. 58, 79\u201382 (2019).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1376_CR57","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/mds.25122","volume":"27","author":"CG Goetz","year":"2012","unstructured":"Goetz, C. G., Stebbins, G. T. & Tilley, B. C. Calibration of unified Parkinson\u2019s disease rating scale scores to Movement Disorder Society-unified Parkinson\u2019s disease rating scale scores. Mov. Disord. 27, 1239\u20131242 (2012).","journal-title":"Mov. Disord."},{"key":"1376_CR58","doi-asserted-by":"crossref","unstructured":"Wan X. Wang W., Liu J. & Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med. Res. Methodol. 14, 135 (2014).","DOI":"10.1186\/1471-2288-14-135"},{"key":"1376_CR59","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) \u2013 Version 5.0. Bethesda, MD; 2017 27 (National Institute of Informatics, 2017)."},{"key":"1376_CR60","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne, J. A. C. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898 (2019).","journal-title":"BMJ"},{"key":"1376_CR61","unstructured":"Joanna Briggs Institute. JBI Critical Appraisal Checklist for Case Series (JBI, 2017)."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01376-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01376-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01376-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T22:58:05Z","timestamp":1786316285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01376-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1376"],"URL":"https:\/\/doi.org\/10.1038\/s41531-026-01376-x","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"189"}}